In-Vitro Susceptibilities of Voriconazole Against Korean Clinical Aspergillus Isolates / 대한의진균학회지

ABSTRACT

BACKGROUND: Voriconazole is a potent new triazole antifungal agent expected to be particularly useful for the treatment of invasive aspergillosis. However, in vitro susceptibility of voriconazole for clinical strains of Aspergillus species isolated in Korea has not been fully surveyed. OBJECTIVE: We determined minimum inhibitory concentrations (MICs) of voriconazole for clinical Aspergillus isolates. METHODS: A total of 100 clinical isolates of Aspergillus species (40 A. fumigatus, 24 A. flavus, 17 A. niger, 17 A. terreus and 2 A. nidulans) was tested. In vitro voriconazole susceptibility testing was accomplished utilizing the National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution method M38-A. MIC of voriconazole was determined using RPMI medium at 48 h of incubation. RESULTS: Among the 100 isolates of Aspergillus species tested, 98% were inhibited by or =2 microgram/mL were 0/40 (0%) in A. fumigatus, 1/24 (4%) in A. flavus, 1/17 (6%) in A. niger, 0/17 (0%) in A. terreus, and 0/2 (0%) in A. nidulans. CONCLUSION: These data demonstrate promising in-vitro activity of voriconazole against clinical strains of Aspergillus species isolated from Korean patients.